{
  "source": "PA-Notification-CGRP-Receptor-Antagonists.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Program\nProgram Number 2025 P 1247-12\nProgram Prior Authorization/Notification\nMedication Aimovig® (erenumab), Ajovy® (fremanezumab)*, Emgality®\n(galcanezumab)\nP&T Approval Date 6/2018, 10/2018, 7/2019, 7/2020, 11/2020, 7/2021, 3/2022, 5/2022,\n5/2023, 3/2024, 6/2024, 2/2025 2/2025\nEffective Date 5/1/2025\n1. Background:\nAimovig, Ajovy* and Emgality 120 mg are calcitonin gene-related peptide (CGRP) receptor\nantagonists indicated for the preventive treatment of migraine in adults. The 100 mg strength of\nEmgality is indicated for the treatment of episodic cluster headache in adults.\n2. Coverage Criteriaa:\nA. Migraines\n1. Initial Therapy\na. Aimovig, Ajovy* or Emgality (120 mg strength) will be approved based upon all of\nthe following criteria:\n(1) Diagnosis of migraines\n-AND-\n(2) Used for the preventive treatment of migraines\n-AND-\n(3) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines (e.g., Nurtec® ODT,\nQulipta®, Vyepti®^)\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Aimovig, Ajovy* or Emgality (120 mg strength) will be approved based on both of\nthe following criteria:\n(1) Patient has experienced a positive response to therapy, demonstrated by a reduction\nin headache frequency and/or intensity\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines (e.g., Nurtec ODT,\nQulipta, Vyepti^)\nAuthorization will be issued for 12 months\nB. Episodic Cluster Headache\n1. Initial Therapy\na. Emgality (100 mg strength) will be approved based upon all of the following criteria:\n(1) Diagnosis of episodic cluster headache\n-AND-\n(2) Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days,\nseparated by pain-free periods lasting at least three months.\n-AND-\n(3) Medication will not be used in combi",
    "ND-\n(2) Patient has experienced at least 2 cluster periods lasting from 7 days to 365 days,\nseparated by pain-free periods lasting at least three months.\n-AND-\n(3) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraines (e.g. Aimovig, Ajovy*,\nNurtec ODT, Qulipta, Vyepti^)\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Emgality (100 mg strength) will be approved based on both of the following criteria:\n(1) Patient has experienced a positive response to therapy, demonstrated by a\nreduction in headache frequency and/or intensity\n-AND-\n(2) Medication will not be used in combination with another CGRP antagonist or\ninhibitor used for the preventive treatment of migraine (e.g. Aimovig, Ajovy*,\nNurtec ODT, Qulipta, Vyepti^)\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n*Ajovy is typically excluded from coverage\n^ Vyepti may be subject to additional benefit and coverage review requirements.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Medical Necessity, Step Therapy and Supply limits may be in place.\n4. References:\n1. Aimovig [package insert]. Thousand Oaks, CA: Amgen Inc; August 2024.\n2. Ajovy [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; October 2022.\n3. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2021.\n4. International Headache Society (IHS); Headache Classification Committee. The\nInternational Classification of Headache",
    "Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2021.\n4. International Headache Society (IHS); Headache Classification Committee. The\nInternational Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38:1-\n211.\n5. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention\nof migraine: An American Headache Society position statement update. AHS Consensus\nStatement. Headache. 2024;41:333-41.\nProgram Prior Authorization/Notification – CGRP antagonists\nChange Control\n6/2018 New program\n10/2018 Added Ajovy and Emgality. Updated references.\n7/2019 Added the episodic cluster headache indication and included approvable\nstrength for episodic and chronic migraine.\n7/2020 Annual review. Updated initial authorization duration.\n11/2020 Updated to note not to be used in combination with another biologic CGRP.\nAdded that Ajovy is typically excluded from coverage.\n7/2021 Annual review. Added statement regarding concomitant therapy with other\npreventive CGRPs. Updated references.\n3/2022 Added Qulipta as CGRP to not be used in combination with. Updated the\nproducts typically excluded from coverage. Added note for Vyetpi\nregarding additional benefit and coverage review requirements. Updated\nreferences.\n5/2022 Combined the episodic and chronic migraine criteria and removed the\nmigraine and headache days.\n5/2023 Annual review. Added state mandate language. Updated references.\n3/2024 Annual review. Increased the initial authorization to 12 months. Updated\nreferences.\n6/2024 Removed notation that Qulipta is typically excluded from coverage.\nUpdated references.\n2/2025 Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}